Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D0A9GI
|
|||
Former ID |
DND000031
|
|||
Drug Name |
ILV-095
|
|||
Synonyms |
PF-05212368, WAY-264095
Click to Show/Hide
|
|||
Drug Type |
Antibody
|
|||
Indication | Psoriasis vulgaris [ICD-11: EA90; ICD-9: 696] | Phase 1 | [1] | |
Company |
Wyeth; pfizer
|
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Interleukin-22 (IL22) | Target Info | . | [2] |
NetPath Pathway | IL9 Signaling Pathway |
References | Top | |||
---|---|---|---|---|
REF 1 | ClinicalTrials.gov (NCT01010542) Study Evaluating Single Dose Of ILV-095 In Psoriasis Subjects. U.S. National Institutes of Health. | |||
REF 2 | Emerging Therapies for the Treatment of Psoriasis. Dermatol Ther (Heidelb) 2012 December; 2(1): 16. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.